Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.43 |
| ▸ | FLT1 | P17948 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | GCGR | P47871 | 1/20 | 0.42 |
| ▸ | TEK | Q02763 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6502553 | 0.83 | SMO (0.51) | TRPV1NR3C1 | |
| SCHEMBL6502528 | 0.81 | TRPV1 (0.42) | ALOX15GCGRTRPV1 | |
| SCHEMBL6488352 | 0.81 | SMO (0.45) | KDRALOX15GCGR | |
| SCHEMBL6800838 | 0.80 | SMO (0.53) | KDRTRPV1 | |
| SCHEMBL6488609 | 0.80 | SMO (0.53) | TRPV1NR3C1 | |
| SCHEMBL6681703 | 0.80 | S1PR1 (0.44) | KDRFLT1 | |
| SCHEMBL6488178 | 0.79 | SMO (0.52) | TRPV1NR3C1 | |
| SCHEMBL6490835 | 0.77 | SMO (0.50) | TRPV1NR3C1 | |
| SCHEMBL6489790 | 0.77 | TRPV1 (0.50) | TRPV1NR3C1 | |
| SCHEMBL6501149 | 0.77 | TRPV1 (0.50) | GCGRTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | KDR 1123/4885FLT1 1224/4885ALOX15 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.